文献速递妇科

循环肿瘤HPV DNA扩展亚型检测可靠识别晚期宫颈癌

Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer.
PubMed 文献 · Gynecol Oncol · 2026-01-01

一项多中心前瞻性研究纳入80例HPV阳性高级别宫颈病变或宫颈癌患者,采用NavDx数字PCR检测血清TTMV-HPV DNA(14种亚型)。晚期宫颈癌灵敏度90%,早期39.2%,复发62.5%,特异性100%;DNA评分动态变化与治疗反应对应。

要点

  • TTMV-HPV DNA对晚期宫颈癌灵敏度90%,对早期仅39.2%。
  • 所有CIN2/3和良性病例TTMV-HPV DNA均不可测,特异性100%。
  • DNA评分动态变化与疾病进展或持续相对应。

核心结论

  • TTMV-HPV DNA是晚期宫颈癌敏感且特异的生物标志物,评分动态对应治疗反应。

研究设计与样本

  • 多中心前瞻性研究纳入80例HPV阳性高级别宫颈病变或宫颈癌患者,治疗前、中、后采集血清。

主要发现

  • 46例(57.5%)宫颈癌,26例(32.5%)CIN2/3,8例(10.0%)良性。
  • 宫颈癌中38例(82.6%)原发,8例(17.4%)复发;原发者28例(73.7%)I/II期,10例(26.3%)III/IV期。
  • 所有CIN2/3和良性病例TTMV-HPV DNA均不可测。
  • 7例疾病进展或持续者TTMV-HPV DNA评分相应升高。

关键数值与推荐

  • TTMV-HPV DNA检测宫颈癌特异性100%(95% CI: 89.7%-100.0%),涵盖所有分期。
  • I/II期灵敏度39.2%(95% CI: 21.5-59.4%)。
  • III/IV期灵敏度90%(95% CI: 55.5-99.7%)。
  • 复发时灵敏度62.5%(95% CI: 24.4-91.48%)。

临床怎么用

  • 可用于HPV相关宫颈癌治疗前评估及治疗中动态监测,尤其对晚期和复发患者。
  • 早期宫颈癌灵敏度有限,阴性结果不能排除早期病变。

局限性

  • 样本量小,早期和复发亚组置信区间宽。
  • 灵敏度与特异性仅基于治疗前评分计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To demonstrate the detection of circulating human papillomavirus (HPV) DNA fragments can serve as a biomarker for presence of tumor and provide a universal, non-invasive tool for monitoring treatment response in HPV-related cervical cancers (CC). METHODS: A multi-site prospective study of HPV-positive high-grade cervical dysplasia (CIN2/3) and CC was conducted. Serum samples were collected pre-, during, and post-treatment. NavDx® (Naveris,Inc) digital droplet polymerase chain reaction testing was used to detect tumor tissue modified viral (TTMV)-HPV DNA. The expanded panel included 14 HPV subtypes. Sensitivity and specificity were calculated for the pre-treatment Score only. Scores were quantified for on-treatment timepoints and trends were compared against treatment response. RESULTS: 80 patients were included in the analysis: 46 (57.5%) CC, 26 (32.5%) CIN2/3, 8 (10.0%) benign. TTMV-HPV DNA was undetectable in all CIN 2/3 and benign cases. For CC, 38 (82.6%) had primary disease and 8 (17.4%) recurrent. For primary CC, 28 (73.7%) had stage I/II and 10 (26.3%) stage III/IV. Specificity for TTMV-HPV DNA for CC detection was 100% (95% CI: 89.7%-100.0%) for all stages. Sensitivity was 39.2% (95% CI: 21.5-59.4%) for stage I/II, 90% (95% CI: 55.5-99.7%) for stage III/IV, and 62.5% (95% CI: 24.4-91.48%) at recurrence. Disease progression/persistence occurred in 7 patients with corresponding increased Scores. CONCLUSIONS: TTMV-HPV DNA is a sensitive and specific biomarker for advanced CC, with Scores dynamically corresponding to treatment response, and has the potential to serve an unmet need as a universal biomarker for patients with HPV-related CC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rothnie K, Tristano E, Diaz-Rodriguez M, et al. Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer. Gynecol Oncol. 2026. PMID: 42000375. doi:10.1016/j.ygyno.2026.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。